Join the Community

22,103
Expert opinions
44,093
Total members
404
New members (last 30 days)
189
New opinions (last 30 days)
28,704
Total comments

ESMA sheds light on OTC trade reporting under No-Deal

ESMA has released a statement which amongst other things includes clarification for EU investment firms that they will have to publish their OTC trades via an EU APA if a UK counterparty is involved. Whilst in Europe this approach may serve to ensure post-trade transparency within the EU27, it is also true that the UK counterparty could be required to publish that trade to a UK APA. This sounds to me like a recipe for a return to the problem of OTC duplicate reporting, despite MiFID II’s decade in the making efforts to improve on that situation.

In case of a no-deal Brexit UK firms will become third country counterparties when facing the EU, and with no equivalence granted pan-European participants may end up shedding a bit too much light on OTC volumes.

 

External

This content is provided by an external author without editing by Finextra. It expresses the views and opinions of the author.

Join the Community

22,103
Expert opinions
44,093
Total members
404
New members (last 30 days)
189
New opinions (last 30 days)
28,704
Total comments

Trending

Now Hiring